Clinical Trial Update: Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports results from evaluating pegylated arginine deiminase (ADI-PEG 20) in patients with metastatic melanoma that cannot be surgical…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ADI-PEG 20 (Pegylated arginine deiminase) (pegylated arginine deiminase)

Snippet

Sponsor: University of Miami | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED | Results posted: 2013-05-01